NO971966D0 - Proteinkinase NPK-110 - Google Patents

Proteinkinase NPK-110

Info

Publication number
NO971966D0
NO971966D0 NO971966A NO971966A NO971966D0 NO 971966 D0 NO971966 D0 NO 971966D0 NO 971966 A NO971966 A NO 971966A NO 971966 A NO971966 A NO 971966A NO 971966 D0 NO971966 D0 NO 971966D0
Authority
NO
Norway
Prior art keywords
protein kinase
npk
alzheimer
maps
cancer
Prior art date
Application number
NO971966A
Other languages
English (en)
Other versions
NO971966L (no
Inventor
Eckhard Mandelkow
Eva-Maria Mandelkow
Jacek Biernat
Gerard Drewes
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of NO971966D0 publication Critical patent/NO971966D0/no
Publication of NO971966L publication Critical patent/NO971966L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO971966A 1994-10-28 1997-04-28 Proteinkinase NPK-110 NO971966L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94117122 1994-10-28
PCT/EP1995/004258 WO1996013592A2 (en) 1994-10-28 1995-10-30 Protein kinase npk-110

Publications (2)

Publication Number Publication Date
NO971966D0 true NO971966D0 (no) 1997-04-28
NO971966L NO971966L (no) 1997-06-19

Family

ID=8216419

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971966A NO971966L (no) 1994-10-28 1997-04-28 Proteinkinase NPK-110

Country Status (12)

Country Link
US (2) US6579691B1 (no)
EP (1) EP0791067B1 (no)
JP (1) JPH10508199A (no)
KR (1) KR100275591B1 (no)
CN (1) CN1168699A (no)
AT (1) ATE417930T1 (no)
CA (1) CA2203910A1 (no)
DE (1) DE69535901D1 (no)
HU (1) HUT77081A (no)
NO (1) NO971966L (no)
NZ (1) NZ295371A (no)
WO (1) WO1996013592A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0618968T3 (da) * 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
WO1998049276A1 (en) * 1997-04-28 1998-11-05 Helix Research Institute Serine/threonine protein kinase
EP1294896A2 (en) * 2000-04-25 2003-03-26 Millennium Pharmaceuticals, Inc. 13295 novel protein kinase molecules and uses therefor
CA2429641A1 (en) * 2000-12-06 2002-06-13 Incyte Genomics, Inc. Kinases and phosphatases
US7119185B2 (en) * 2000-12-21 2006-10-10 Trustees Of The University Of Pennsylvania Hormonally up-regulated, neu-tumor-associated kinase
AU2002254029A1 (en) * 2001-02-27 2002-09-12 Daniel L. Alkon Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
DE60237917D1 (de) 2001-06-05 2010-11-18 Exelixis Inc Gfats als modifikatoren des p53-wegs und verwendungsverfahren
US6492156B1 (en) * 2001-10-31 2002-12-10 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2005010148A2 (en) * 2003-06-19 2005-02-03 Exelixis, Inc. Marks as modifiers of the pten pathway and methods of use
US8273536B2 (en) 2003-06-19 2012-09-25 Exelixis, Inc. Marks as modifers of the PTEN pathway and methods of use
CN100424184C (zh) * 2005-12-09 2008-10-08 浙江大学 疱疹类病毒基因芯片及其应用
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
KR101294725B1 (ko) 2010-12-30 2013-08-08 연세대학교 산학협력단 인산화된 ｇｒａｓｐ를 포함하는 낭포성섬유증 치료용 약학 조성물
ME03008B (me) * 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN117551674B (zh) * 2023-11-20 2024-10-18 内蒙古农业大学 沙葱萤叶甲微管亲和调节激酶GdMARK2基因的克隆及其功能

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease

Also Published As

Publication number Publication date
MX9703101A (es) 1998-07-31
CA2203910A1 (en) 1996-05-09
DE69535901D1 (de) 2009-01-29
EP0791067A2 (en) 1997-08-27
AU714636B2 (en) 2000-01-06
US20030104516A1 (en) 2003-06-05
NO971966L (no) 1997-06-19
US20040038361A1 (en) 2004-02-26
WO1996013592A3 (en) 1996-08-01
US7485712B2 (en) 2009-02-03
CN1168699A (zh) 1997-12-24
US6579691B1 (en) 2003-06-17
EP0791067B1 (en) 2008-12-17
HUT77081A (hu) 1998-03-02
KR100275591B1 (ko) 2001-02-01
JPH10508199A (ja) 1998-08-18
AU3870295A (en) 1996-05-23
ATE417930T1 (de) 2009-01-15
WO1996013592A2 (en) 1996-05-09
NZ295371A (en) 1998-11-25

Similar Documents

Publication Publication Date Title
ATE417930T1 (de) Proteinkinase npk-110
EP0683234A4 (en) ANTIBODIES DIRECTED AGAINST -g (b) -AMYLOID OR A DERIVATIVE THEREOF AND ITS USE.
ATE549347T1 (de) Gene von säugetiere, und damit verbundene reagentien, methoden
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
AR038568A1 (es) Anticuerpos anti-a beta y su uso
FI925986A0 (fi) Slumpartat bio-oligomer bibliotek, ett foerfarande foer syntetisering avdet samt ett foerfarande foer anvaendning av det
PT737207E (pt) Inibidores de plasmina humana derivados de dominios kunitz
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
MX9709913A (es) Metaloconstrucciones determinadas estructuralmente y aplicaciones.
WO2002057259A3 (en) Pyrazole compounds useful as protein kinase inhibitors
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EA200101037A1 (ru) Соединения и способы для лечения и диагностики рака легкого
ATE418563T1 (de) Nik proteine, nukleinsäure sowie verfahren
MXPA02008239A (es) Gen humano de la esquizofrenia.
ATE212065T1 (de) Nukleinsäuremoleküle mit der fähigkeit zur unterscheidung von prpc und prpsc-prionprotein- isoformen und verfahren zu deren herstellung
WO2003028543A3 (en) Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
WO2003105773A3 (en) Activating mutations of platelet derived growth factor receptor alpha (pdgfra) as diagnostic markers and therapeutic targets:
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
DE69728897D1 (de) Saeugetierchemokine
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
EP0815240A4 (en) NEW HUMAN PROTEINS, LIKE CYCLINE-DEPENDENT KINASES, AND METHODS TO USE THEM
ATE219247T1 (de) Methoden zur feststellung von alzheimerscher krankheit
WO2001064876A3 (en) Human schizophrenia gene
EP0780472A3 (en) Stress proteins
WO2003060067A3 (en) P85-alpha nucleic acids, polypeptides and related methods

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application